Horizon Pharma (HZNP) Stock Tanks on Mixed Earnings

NEW YORK (TheStreet) -- Horizon Pharma (HZNP) closed trading down 6.02% to $27.62 on Friday after the pharmaceutical company released its first-quarter earnings results before the opening bell today.

The company reported a first-quarter net loss of $19.6 million, or 21 cents per share on an adjusted basis, missing analysts' consensus estimates of 23 cents per share by 2 cents. Revenue for the period rose 118% to $113.1 million, topping analysts estimates of $103.7 million.

The company also issued full-year revenue guidance between $590 million and $610 million, well above analysts' $539 million expectations for the year.

Separately, the company announced that it settled patent infringement litigation with generic drug maker Perrigo (PRGO) that grants Perrigo non-exclusive rights to market a generic version of Horizon's arthritis ointment, Pennsaid, in the U.S.

Horizon shares are up 0.36% to $27.72 in after-hours trading today.

HZNP Chart HZNP data by YCharts

Must Read:
Warren Buffett's Top 25 Stocks for 2015

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Dow Scores Ninth Straight Record Close With Tiny Gains, S&P 500 at All-Time High

Dow Is Back on Track to Close at a Record High as Consumer Staples Lead

Energy Losses Put Dow's Record-Breaking Streak in Jeopardy

Biotech Movers: Second Quarter Results, Increased Outlook Send Horizon Pharma Shares Higher